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Background: Standard therapies for high grade glioma have failed to substantially improve survival and are
associated with significant morbidity. At relapse, high grade gliomas, such as glioblastoma multiforme, are refractory
to therapy and universally fatal. BRAF V600E-mutations have been described in a modest 6% to 7% of primary
central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain
tumor subtypes. The use of BRAF inhibitors have transformed melanoma therapy however their use in brain tumors
remains unproven.
Case presentation: We describe the pediatric case of a now 12 year old Caucasian male who originally presented
at age 9 with a right fronto-parietal glioblastoma multiforme that recurred 2 ½ years from diagnosis. Molecular
analysis of the primary tumor revealed a BRAF V600E mutation and the patient was placed on the BRAF inhibitor
vemurafenib. A complete response was observed after 4 months of therapy and remains sustained at 6 months.
Conclusion: This is the first report of a complete response of relapsed glioblastoma multiforme to targeted BRAF
inhibitor therapy. While not a predominant mutation in glioblastoma multiforme, the increased prevalence of BRAF
V600 mutations in pediatric CNS tumors and certain subtypes marks a population to whom this therapy could be
applied. Response to this therapy suggests that BRAF inhibitors can affect primary CNS lesions when a documented
and targetable mutation is present.
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The highest incidence of CNS tumors that harbor BRAF
V600E-mutations occurs in pediatric patients [1]. In par-
ticular, a relatively high frequency of these mutations has
been identified in pediatric pilocytic astrocytomas, pleo-
morphic xanthoastrocytomas, malignant astrocytomas,
gangliogliomas, and the epithelioid subtype of glioblast-
oma multiforme [1-4]. Although BRAF inhibitors extend
survival and improve the quality of life in patients with
BRAF V600E-mutated melanoma [5,6], variable responses
to BRAF inhibitors have been described in different tumor
types [7]. Additionally, although melanoma that has me-
tastasized to the CNS responds to BRAF inhibitors [6],
these metastases do not have an intact blood–brain barrier* Correspondence: giles.robinson@stjude.org
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unless otherwise stated.[8], which frequently blocks an agent’s ability to reach
CNS tumors at exposures and concentrations necessary to
achieve the desired pharmacologic effect. Therefore, it is
unclear whether BRAF inhibition can clinically affect a pri-
mary CNS lesion as it does a secondary one. Here we de-
scribe the first known case of complete response in a
BRAF V600E-mutated high-grade glioma to vemurafenib
(BRAF inhibitor) therapy.
Case presentation
A 9-year-old patient presented with a one-week onset of
progressive left-sided weakness. His symptoms were first
noted by his father when the boy had difficulty extending
the fingers on his left hand to catch an American football.
Within a few days, a left leg limp and the beginnings of
a left-sided facial droop had developed. Magnetic reson-
ance imaging (MRI) revealed a large (7 cm × 5 cm× 5 cm),
spherical heterogeneously enhancing, mixed cystic andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tension into the internal capsule, thalamus, and basal
ganglia (Figure 1A). The solid tumor elements demon-
strated restricted diffusion suggestive of high-grade
tumor activity. A stereotactic right fronto-parietal cra-
niotomy was performed, and the vast majority of the
tumor was successfully removed (Figure 1B); however,
the most medial structures of the right internal capsule
and thalamus were spared an aggressive resection toFigure 1 Chronological changes on magnetic resonance imaging (MR
T1-weighted images with gadolinium-based contrast were taken at the foll
of radiation therapy, (D) while receiving adjuvant chemotherapy, (E) at com
(G) upon start of vemurafenib therapy at relapse, (H) after 2 months of vempreserve the patient’s neurologic function. Upon histo-
pathologic review, the tumor consisted of a diffusely
infiltrating glial neoplasm. The hypercellular tumor
demonstrated mitotic activity, vascular proliferation,
and palisading necrosis (Figure 2A and B), fulfilling
criteria for glioblastoma (WHO grade IV). While not
the dominant morphology, focally the tumor demon-
strated features of the epithelioid variant of glioblast-
oma (Figure 2C).I) document the tumor recurrence and response. Coronal MRI
owing times: (A) diagnosis, (B) post-operatively, (C) after completion
pletion of therapy, (F) 4 months after completion of therapy,
urafenib therapy, and (I) after 4 months of vemurafenib therapy.
Figure 2 The diagnosis of glioblastoma (WHO grade IV) was rendered on histopathologic review. Histopathologic evaluation revealed a
hypercellular astrocytic neoplasm which infiltrated the surrounding brain parenchyma. Mitotic activity (arrows) was abundant and microvascular
proliferation (designated V) was present (A). Necrosis was encountered in the specimen, including pseudo-palisading necrosis (designated N) (B).
While not a dominant appearance, focally the tumor had features of epithelioid glioblastoma (C).
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right thalamus, consistent with the operative description of
remnants of tumor in this location. After recovering from
surgery, the patient was treated with a best clinical manage-
ment plan. Focal radiation of 59.4 Gy to the tumor bed was
administered in combination with vorinostat (230 mg/m2/
dose 5 days/week) therapy as a radiosensitizer over a 6-
week period. After a 4 week break, he received combination
chemotherapy with bevacizumab (10 mg/kg/dose every
2 weeks), topotecan (0.8 mg/m2/dose days 1–10), and vori-
nostat (180 mg/m2/dose days 1–14) administered over
28-day cycles. Regular MRI scans of the patient showed no
evidence of disease progression while he was on therapy
(Figure 1C-E), and what had previously been reported on
radiology reports as residual disease in the thalamus was
reported as probable enhancing gliosis with suspected re-
gional mineralization. After a total of 24 months of therapy,
he was taken off therapy and monitored with serial brain
MRI on a tri-monthly basis.
Four months after stopping therapy, an area of new en-
hancement became apparent (Figure 1F). This focus was
deep in the patient’s right thalamus and more medial to
where the original residual disease was suspected to be.
This focus was of concern because it arose within a region
that was always closely monitored due to the presence of
T2 prolongation. But the focus was initially small and
thought to represent a nonspecific change within a heavily
treated region. Subsequent scans, however, showed this
focus to be enlarging (Figure 1F-G) with increased perfu-
sion, consistent with a recurrent and progressive tumor.
By 8 months from the end of therapy, this mass had a 1-
cm diameter (Figure 1G), and the patient and family were
informed that this was almost certainly a recurrent tumor.
Given the absence of symptoms in the patient, the infil-
trative nature of the disease, and the location of the tumor
focus deep in the thalamus, an attempt at surgical resec-
tion was judged to be a poor option with a high chance ofmorbidity and almost no chance of safely removing all
microscopic disease. Similarly, the risk of biopsy did not
outweigh the benefits of a histologic confirmation of an
already highly malignant tumor. Re-initiation of the prior
chemotherapy regimen was considered but not felt to be
indicated because, in retrospect, the enhancing lesion
was found to be present in a punctate form on the pa-
tient’s imaging just prior to stopping therapy (Figure 1E).
Therefore, the pathology of the original tumor was again
reviewed with this recurrence and additional molecular
characterization of the tumor was performed. Based on
the focal features of epithelioid glioblastoma multiforme, a
variant previously reported to have a high proportion of
BRAF abnormalities [2], BRAF V600E testing was per-
formed on material extracted from the paraffin embedded
tissue. By PCR amplification and subsequent sequencing,
a BRAF V600E mutation was detected in the patient sam-
ple (Figure 3).
Vemurafenib, a BRAF inhibitor recently approved by
the United States Food and Drug Administration for
therapy of melanoma with a V600E mutation, was initi-
ated as an off-label use. The child’s therapy was started
at 720 mg by mouth twice daily for 28 days (about
600 mg/m2 per dose), which approximates the recom-
mended adult dose of 920 mg by mouth twice daily.
Two months from initiation of therapy, a follow-up MRI
showed a partial response (Figure 1H). Four months
from initiation of therapy, the recurrent tumor was no
longer detectable by MRI (Figure 1I) and this effect con-
tinued through a six month MRI evaluation.
Therapy was initially halted after the first 5 consecutive
days because a severe diffuse erythematous palpable fol-
licular rash developed. When this rash almost completely
resolved after 8 days off the medication, the drug was re-
sumed at the same dose. The rash returned in a milder
form and remained stable except for occasional flares in
sun- and wind-exposed areas. Additional adverse events
Figure 3 Electropherogram derived from patient’s tumor
sample showing a point mutation at codon 600 (GTG to GAG)
resulting in a Valine (V) to Glutamic acid (E) substitution.
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texture. Serial dermatologic exams revealed no evidence of
dysplastic or neoplastic skin lesions, and family members
were encouraged to adhere to strict precautions in the
sun. Serial EKGs showed no prolongation of the corrected
QT interval, and serial eye exams showed no ocular effects
of the medication. The patient is on his seventh cycle of
therapy under stringent observation.
Conclusions
A complete response of a CNS tumor to BRAF inhibitor
therapy underscores the need to fully investigate these
targeted drugs in patients with CNS tumors which har-
bor BRAF mutations. While interest in utilizing these
drugs in the CNS population has been rising, there has
been little data to suggest that these drugs will be effect-
ive in these circumstances. This case suggests that a
drug of this class can penetrate a primary brain tumor
and affect a primary CNS lesion harboring a BRAF mu-
tation. A dramatic response of this nature, however,
must be received with cautious optimism.
The experience of BRAF inhibition in other tumor types
suggests that response is unlikely to be uniform across all
CNS tumors, even in the presence of similar V600 mu-
tations. Already, a sampling of four adult patients with
BRAF V600E-mutated pleomorphic xanthoastrocytomas
treated with vemurafenib shows that the best documented
response is a modest, partial response [9]. Two pediatric
patients with BRAF V600E mutated gangliogliomas have
now been reported to have a sustained partial response
while another two patients, one ganglioglioma and the
other a malignant astrocytoma, had a transient (< 2 month)
and no response, respectively [10,11]. While our casedemonstrates that aggressive high grade gliomas can
respond, pathways of resistance may already exist within
these tumors. Reports in colorectal cancer suggest
BRAF-mutant tumors may escape inhibition by amplify-
ing receptor tyrosine kinases, such as epidermal growth
factor receptor (EGFR), and EGFR amplification and fu-
sion are common alterations found in adult glioblast-
oma multiforme lesions [7,12]. Moreover, the response
of CNS tumors with alternative BRAF abnormalities,
such as alternate V600 mutations or fusions, will also
need to be investigated. Preclinical data suggest that
BRAF fusions, which are widespread in pilocytic astro-
cytoma, may not be as responsive to BRAF inhibitors as
V600-mutated tumors are [13].
Unanticipated side effects are bound to surface, and the
susceptible and vulnerable pediatric population will pre-
dictably remain at high risk. For example, blocking RAF
kinase has been shown to paradoxically upregulate its acti-
vator RAS, leading to the formation of skin neoplasias and
to the progression of RAS-mutated malignancies [14-17].
Therefore, what a blockade of RAF signaling in the MAPK
pathway may do to a young developing child over a life-
time will need to be carefully documented in clinical trials.
The melanoma experience suggests that resistance will
surely emerge in CNS tumors responsive to this therapy
[14,18]. Therefore, coadministration with other MAPK
pathway inhibitors, such as MEK inhibitors, will need to
be investigated to prevent resistance from MAPK pathway
reactivation [19,20]. Also, coadministration with alterna-
tive survival pathway inhibitors, such as PI3K inhibitors
and VEGF inhibitors, may need to be evaluated [20].
In conclusion, this case provides evidence that BRAF
inhibition has important therapeutic potential in CNS
tumors, including the most aggressive high grade gli-
omas. These and other targeted agents provide hope for
the treatment of advanced and incurable tumors and
may radically improve current therapy. Substantial work
remains to be done before we understand when and
how to best use this new class of drugs, however the
identification of the potential responders through careful
histologic and mutational analysis is critical. Even if the
effect of this targeted therapy remains temporary, thera-
peutic goals could include extending survival and im-
proving quality of life in patients with relapsed disease,
improving the extent of surgical resection of a tumor,
and increasing time to radiation in order to preserve a
child’s neurocognitive development.Consent
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